Atripla (efavirenz 600mg/emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) was developed through a joint venture partnership between Bristol-Myers Squibb and Gilead Sciences. Atripla combines sustiva (efavirenz) manufactured by Bristol-Myers Squibb, and truvada (emtricitabine/tenofovir disoproxil fumarate) manufactured by Gilead Sciences.
Mark Wainberg, director of the McGill AIDS Centre and professor of medicine and microbiology at McGill University, said: “Atripla represents a milestone in treatment for this disease. I commend the companies involved for joining forces to make Atripla, the first complete three-drug regimen in a single once-daily pill.”